These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Human monoclonal antibodies that neutralize anthrax toxin by inhibiting heptamer assembly. Wang F; Ruther P; Jiang I; Sawada-Hirai R; Sun SM; Nedellec R; Morrow PR; Kang AS Hum Antibodies; 2004; 13(4):105-10. PubMed ID: 15671576 [TBL] [Abstract][Full Text] [Related]
7. Human monoclonal antibody AVP-21D9 to protective antigen reduces dissemination of the Bacillus anthracis Ames strain from the lungs in a rabbit model. Peterson JW; Comer JE; Baze WB; Noffsinger DM; Wenglikowski A; Walberg KG; Hardcastle J; Pawlik J; Bush K; Taormina J; Moen S; Thomas J; Chatuev BM; Sower L; Chopra AK; Stanberry LR; Sawada R; Scholz WW; Sircar J Infect Immun; 2007 Jul; 75(7):3414-24. PubMed ID: 17452469 [TBL] [Abstract][Full Text] [Related]
8. A three-dose intramuscular injection schedule of anthrax vaccine adsorbed generates sustained humoral and cellular immune responses to protective antigen and provides long-term protection against inhalation anthrax in rhesus macaques. Quinn CP; Sabourin CL; Niemuth NA; Li H; Semenova VA; Rudge TL; Mayfield HJ; Schiffer J; Mittler RS; Ibegbu CC; Wrammert J; Ahmed R; Brys AM; Hunt RE; Levesque D; Estep JE; Barnewall RE; Robinson DM; Plikaytis BD; Marano N; Clin Vaccine Immunol; 2012 Nov; 19(11):1730-45. PubMed ID: 22933399 [TBL] [Abstract][Full Text] [Related]
9. In vitro and in vivo characterization of anthrax anti-protective antigen and anti-lethal factor monoclonal antibodies after passive transfer in a mouse lethal toxin challenge model to define correlates of immunity. Staats HF; Alam SM; Scearce RM; Kirwan SM; Zhang JX; Gwinn WM; Haynes BF Infect Immun; 2007 Nov; 75(11):5443-52. PubMed ID: 17709410 [TBL] [Abstract][Full Text] [Related]
10. Prophylaxis and therapy of inhalational anthrax by a novel monoclonal antibody to protective antigen that mimics vaccine-induced immunity. Vitale L; Blanset D; Lowy I; O'Neill T; Goldstein J; Little SF; Andrews GP; Dorough G; Taylor RK; Keler T Infect Immun; 2006 Oct; 74(10):5840-7. PubMed ID: 16988263 [TBL] [Abstract][Full Text] [Related]
11. Neutralizing activity of vaccine-induced antibodies to two Bacillus anthracis toxin components, lethal factor and edema factor. Taft SC; Weiss AA Clin Vaccine Immunol; 2008 Jan; 15(1):71-5. PubMed ID: 18032590 [TBL] [Abstract][Full Text] [Related]
12. Human monoclonal anti-protective antigen antibody for the low-dose post-exposure prophylaxis and treatment of Anthrax. Tang Q; Xiong S; Liang X; Kuai X; Wang Y; Wang C; Feng Z; Zhu J BMC Infect Dis; 2018 Dec; 18(1):640. PubMed ID: 30526504 [TBL] [Abstract][Full Text] [Related]
13. Human monoclonal antibodies against anthrax lethal factor and protective antigen act independently to protect against Bacillus anthracis infection and enhance endogenous immunity to anthrax. Albrecht MT; Li H; Williamson ED; LeButt CS; Flick-Smith HC; Quinn CP; Westra H; Galloway D; Mateczun A; Goldman S; Groen H; Baillie LW Infect Immun; 2007 Nov; 75(11):5425-33. PubMed ID: 17646360 [TBL] [Abstract][Full Text] [Related]
14. Induction of protective immunity to anthrax lethal toxin with a nonhuman primate adenovirus-based vaccine in the presence of preexisting anti-human adenovirus immunity. Hashimoto M; Boyer JL; Hackett NR; Wilson JM; Crystal RG Infect Immun; 2005 Oct; 73(10):6885-91. PubMed ID: 16177368 [TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of AVP-21D9, an anthrax monoclonal antibody, in animal models and humans. Malkevich NV; Hopkins RJ; Bernton E; Meister GT; Vela EM; Atiee G; Johnson V; Nabors GS; Aimes RT; Ionin B; Skiadopoulos MH Antimicrob Agents Chemother; 2014 Jul; 58(7):3618-25. PubMed ID: 24733473 [TBL] [Abstract][Full Text] [Related]
16. Human monoclonal antibodies generated following vaccination with AVA provide neutralization by blocking furin cleavage but not by preventing oligomerization. Smith K; Crowe SR; Garman L; Guthridge CJ; Muther JJ; McKee E; Zheng NY; Farris AD; Guthridge JM; Wilson PC; James JA Vaccine; 2012 Jun; 30(28):4276-83. PubMed ID: 22425791 [TBL] [Abstract][Full Text] [Related]
17. Generation and Characterization of Human Monoclonal Antibodies Targeting Anthrax Protective Antigen following Vaccination with a Recombinant Protective Antigen Vaccine. Chi X; Li J; Liu W; Wang X; Yin K; Liu J; Zai X; Li L; Song X; Zhang J; Zhang X; Yin Y; Fu L; Xu J; Yu C; Chen W Clin Vaccine Immunol; 2015 May; 22(5):553-60. PubMed ID: 25787135 [TBL] [Abstract][Full Text] [Related]
19. A heterodimer of a VHH (variable domains of camelid heavy chain-only) antibody that inhibits anthrax toxin cell binding linked to a VHH antibody that blocks oligomer formation is highly protective in an anthrax spore challenge model. Moayeri M; Leysath CE; Tremblay JM; Vrentas C; Crown D; Leppla SH; Shoemaker CB J Biol Chem; 2015 Mar; 290(10):6584-95. PubMed ID: 25564615 [TBL] [Abstract][Full Text] [Related]
20. Development of a competitive enzyme linked immunosorbent assay to identify epitope specific antibodies in recipients of the U.S. licensed anthrax vaccine. Gubbins MJ; Schmidt L; Tsang RS; Berry JD; Kabani A; Stewart DI J Immunoassay Immunochem; 2007; 28(3):213-25. PubMed ID: 17613668 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]